Cue Biopharma (CUE) PT Lowered to $27 at Stifel

November 18, 2020 7:51 AM EST
Get Alerts CUE Hot Sheet
Price: $10.46 -0.29%

Rating Summary:
    7 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 37 | New: 115
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Stifel analyst Stephan Willey lowered the price target on Cue Biopharma (NASDAQ: CUE) to $27.00 (from $30.00) after management progressed to single-agent CUE-101 dose-escalation into the 8mg/kg cohort.

The analyst reiterated a Buy rating, stating "we believe safety and immunogenicity should no longer be viewed as theoretical concerns associated with the core Immuno-STAT scaffold. We believe whether there exists a sufficient preexisting pool of antigen-specific T cells within these salvage/no-option HPV+ SCCHN patients capable of Immuno-STAT-mediated activation now remains a key question – although some of the preliminary PD data management continues to share here (directionally-favorable changes in antigen-specific and KI67+ T cell counts vs. baseline) would suggest this is now occurring in some patients. We view the recent initiation of the P1b KEYNOTE-A78 trial evaluating the combination of CUE-101 and pembrolizumab in 1L SCCHN patients as a better opportunity for demonstrating RECIST-defined clinical benefit – but acknowledge any longer-term emergence of unambiguous single-agent CUE-101 activity in the dose-escalation portion will greatly streamline our interpretation/attribution of this benefit".



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst PT Change

Related Entities

Stifel